A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma

Summary

The primary purpose of this study was to see how tasisulam-sodium affected metastatic melanoma when compared against paclitaxel as measured by overall survival.

Timeline

Start

2009-12

Primary completion

2011-03

Completion

2011-03

Outcome

Missed primary endpoint

Stopped: “More possibly treatment-related deaths on tasisulam-sodium arm.”

registry Tasisulam-sodium vs Paclitaxel; p = 0.121; Hazard Ratio (HR) 1.23; Stratified log rank; NCT01006252 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Paclitaxel	Small molecule	80 mg/m2	Intravenous
Subject	Tasisulam	Small molecule	—	Intravenous

Indications